

**REMARKS**

This Amendment is filed in response to the Office Action issued 25 August 2004.

The specification was amended to explicitly recite additional trademarks and registered trademarks.

Claims 1-43 are pending. These claims have been canceled both in light of a restriction requirement and to more particularly recite the subject matter of the examined claims drawn to a stabilized DNA formulation. To this end, new claims 44-68 are entered for examination.

New claims 44-68 more particularly point out and distinctly the formulations of the present invention. These formulations provide for vastly improved plasmid DNA formulations at room temperature while also being compatible and tolerable for parenteral injection in humans in terms of types of excipients used, osmolality, buffering capacity, etc. Applicants respectfully take the position that new claims 44-68 are in condition for allowance. The Examiner is invited to contact the undersigned attorney if clarification is required on any aspect of this response, or if any of the claims are considered to require further amendment to be placed in condition for allowance after entry of this Amendment.

Respectfully submitted,



J. Mark Hand

Reg. No. 36,545

Attorney for Applicants

Merck & Co., Inc.

P.O. Box 2000

Rahway, NJ 07065-0907

(732) 594-3905

Date: 24 SEPTEMBER 2004